BiotechTube
Momentum Biotechnologies

Momentum Biotechnologies

Cambridge, United States· Est.
momentum.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2018 and based in Cambridge, Massachusetts, Momentum Biotechnologies is a specialized, service-based biotech company focused on mass spectrometry-driven drug discovery. It offers end-to-end preclinical services, including binding assays, proteomics, and small molecule analysis, powered by proprietary technology platforms like CysScout and a large fleet of advanced MS instruments. The company's business model is built on providing high-throughput, high-quality data and custom assay development to accelerate the research and development pipelines of its clients, positioning it as a key enabler in the rapidly growing biologics and targeted therapy space.

OncologyImmunologyNeuroscienceMetabolic DiseaseInfectious DiseaseRare Diseases

Technology Platform

A comprehensive mass spectrometry-driven platform featuring an extensive fleet of instruments (RapidFire-MS, ICP-MS, Orbitrap Astral/Ascend) and a suite of proprietary assay technologies (e.g., CysScout, TargetScout, ProteomeScout, KinomeScout) for target discovery, binding assays, proteomics, chemoproteomics, and oligonucleotide analysis.

Opportunities

Strong demand for specialized mass spectrometry services driven by the rise of complex therapeutic modalities like targeted protein degraders, covalent inhibitors, and oligonucleotides.
The ability to productize proprietary proteomic databases offers a scalable, non-service revenue stream.
Geographic expansion through Momentum Europe taps into a growing international market.

Risk Factors

Revenue is vulnerable to downturns in biopharma R&D spending and client funding cycles.
High competition in the CRO space requires continuous and costly technological innovation.
The business is highly dependent on retaining its deep bench of scientific experts in a competitive talent market.

Competitive Landscape

Competes with large, full-service preclinical CROs (e.g., Charles River, LabCorp) and specialized, technology-focused boutiques in mass spectrometry and proteomics. Differentiation is based on proprietary 'Scout' assay platforms, the extensive experience of its core team (including developers of RapidFire-MS), and an end-to-end, modality-agnostic service offering.

More companies in United States →